Panacea Biotec shares rise on UNICEF vaccine contract upgrade
pre-market1 source ↓written by the desknot a recommendation
- revenue visibility
- 2026 and 2027
Panacea Biotec Limited reported a significant upgrade to its UNICEF vaccine supply contract, boosting its share price sharply on 26 December 2025. The revised order for the WHO pre-qualified pentavalent vaccine, Easyfive‑TT®, enhances revenue visibility for 2026 and 2027. This concrete development has led to increased trading volumes and investor interest, even amid a sluggish broader market.
Not investment advice. For informational purposes only.